{
  "company": {
    "name": "Exeliom Biosciences",
    "website": "https://exeliombio.com/",
    "record": "https://startuphistory.org/c/exeliombio.com"
  },
  "status": null,
  "history_since": "2020-08-14T06:02:07.000Z",
  "baseline": {
    "snapshot_id": "8b12a592e6944126aed35abad68314b878929d9e1b63209def60394eb9a38c6e",
    "observed_at": "2020-08-14T06:02:07.000Z",
    "headline": null,
    "description": "Exeliom Biosciences (formerly Nextbiotix) is a preclinical-stage biotechnology company developing monoclonal microbial therapies, single-strains of naturally-occurring commensal bacteria with defined ",
    "evidence": "https://web.archive.org/web/20200814060207/https://www.exeliombio.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T14:08:46.441Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-01-25T03:35:04.000Z",
      "variants": [
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2021-08-05T18:28:53.000Z",
          "evidence": "https://web.archive.org/web/20210805182853/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2022-01-17T01:43:16.000Z",
          "evidence": "https://web.archive.org/web/20220117014316/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2023-01-27T08:40:05.000Z",
          "evidence": "https://web.archive.org/web/20230127084005/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2023-07-04T21:02:30.000Z",
          "evidence": "https://web.archive.org/web/20230704210230/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2024-07-17T10:40:14.000Z",
          "evidence": "https://web.archive.org/web/20240717104014/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2025-01-18T16:40:39.000Z",
          "evidence": "https://web.archive.org/web/20250118164039/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2025-10-21T12:11:56.000Z",
          "evidence": "https://web.archive.org/web/20251021121156/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Crossing the next frontier to give you a fair chance to fight",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2026-01-25T03:35:04.000Z",
          "evidence": "https://web.archive.org/web/20260125033504/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Crossing the next frontier to give you a fair chance to fight",
      "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
      "from": "2021-08-05T18:28:53.000Z",
      "to": "2026-01-25T03:35:04.000Z",
      "captures": 8,
      "evidence": "https://web.archive.org/web/20260125033504/https://www.exeliombio.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-08-05T18:28:53.000Z",
          "to": "2026-01-25T03:35:04.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T14:08:46.441Z",
      "variants": [
        {
          "headline": "Breaking the ICI Ceiling Restoring Innate Immunity to Make Immunotherapy Work",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2026-08-26T18:18:50.000Z",
          "evidence": "https://web.archive.org/web/20260826181850/https://www.exeliombio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Breaking the ICI Ceiling Restoring Innate Immunity to Make Immunotherapy Work",
          "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
          "observed_at": "2026-11-05T14:08:46.441Z",
          "evidence": "https://www.exeliombio.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Breaking the ICI Ceiling Restoring Innate Immunity to Make Immunotherapy Work",
      "subhead": "At Exeliom Biosciences, we develop novel therapeutic approaches to unleashthe therapeutic potential of key players in the Microbiome - Host interactions to fightimmune-mediated diseases, starting with",
      "from": "2026-08-26T18:18:50.000Z",
      "to": "2026-11-05T14:08:46.441Z",
      "captures": 2,
      "evidence": "https://www.exeliombio.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-08-26T18:18:50.000Z",
          "to": "2026-11-05T14:08:46.441Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-76f19820d78886d9b85c22512072b409b8c55211db978f06a44d55cfddb4e43e:0e684c6d60d9211c166f85ef0779406d1bc8131cbf57d20d3e66e3165da8c862:funding:3cbc636c7c71da07",
      "before_evidence": "https://web.archive.org/web/20230704210230/https://www.exeliombio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “in 2016 and headquartered in Paris, Exeliom has raised a total of €24 million ($26M) since its inception.”.",
      "between": {
        "from": "2023-07-04T21:02:30.000Z",
        "to": "2024-07-17T10:40:14.000Z"
      },
      "evidence": "https://web.archive.org/web/20240717104014/https://www.exeliombio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    },
    {
      "n": 2,
      "id": "page-0e684c6d60d9211c166f85ef0779406d1bc8131cbf57d20d3e66e3165da8c862:0409b2975a925c5b0d63f7d21e6dfacad15ee7cefb25063d65db769b8485768b:funding:3cbc636c7c71da07",
      "before_evidence": "https://web.archive.org/web/20240717104014/https://www.exeliombio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “in 2016 and headquartered in Paris, Exeliom has raised a total of €24 million ($26M) since its inception.”.",
      "between": {
        "from": "2024-07-17T10:40:14.000Z",
        "to": "2025-01-18T16:40:39.000Z"
      },
      "evidence": "https://web.archive.org/web/20250118164039/https://www.exeliombio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    },
    {
      "n": 3,
      "id": "page-0409b2975a925c5b0d63f7d21e6dfacad15ee7cefb25063d65db769b8485768b:fbb8b9770c126bfb862faa1b6f4bce2aea6e5d330bbbde8a1f534761da5a3c27:funding:3cbc636c7c71da07",
      "before_evidence": "https://web.archive.org/web/20250118164039/https://www.exeliombio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “in 2016 and headquartered in Paris, Exeliom has raised a total of €24 million ($26M) since its inception.”.",
      "between": {
        "from": "2025-01-18T16:40:39.000Z",
        "to": "2025-10-21T12:11:56.000Z"
      },
      "evidence": "https://web.archive.org/web/20251021121156/https://www.exeliombio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    },
    {
      "n": 4,
      "id": "classifier-b147ee6b558d5250fc1e4220ea087f834f682e26d9971d4bedc6b8416b075e15:61ea075cdfea29a532836319d30167e22a1a822038c8424b4a17ba52137a57be:repositioning",
      "before_evidence": "https://web.archive.org/web/20260125033504/https://www.exeliombio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "repositioning",
      "label": "Messaging",
      "summary": "Changed its homepage headline from “Crossing the next frontier to give you a fair chance to fight” to “Breaking the ICI Ceiling Restoring Innate Immunity to Make Immunotherapy Work”.",
      "between": {
        "from": "2026-01-25T03:35:04.000Z",
        "to": "2026-08-26T18:18:50.000Z"
      },
      "evidence": "https://web.archive.org/web/20260826181850/https://www.exeliombio.com/",
      "evidence_kind": "internet_archive",
      "basis": "classifier",
      "topic": "https://startuphistory.org/t/repositioned"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Exeliom Biosciences” company record, https://startuphistory.org/c/exeliombio.com"
}